Nusa Matijasic1, Aleksandra Bonevski1, Visnja Tokic Pivac2, Ivan Pavic3. 1. Department of Hematology and Oncology, Children's Hospital Zagreb, Zagreb, Croatia. 2. Division of Cardiology, Children's Hospital Zagreb, Zagreb, Croatia. 3. Departments of Pulmonology, Allergology, Immunology, and Rheumatology, Children's Hospital Zagreb, Zagreb, Croatia.
Abstract
Background: Impaired lung function has been detected in up to 65% of all childhood cancer survivors. It is often caused by exposure to radiation therapy and various chemotherapeutics. The first cytotoxic drug ever identified as a causative agent of lung injury was busulfan, reported in the early 1960s. Signs and symptoms of busulfan lung are nonspecific and it is therefore difficult to differentiate the condition from pulmonary impairment caused by other pulmotoxic agents, infections, pulmonary metastases, graft-versus-host disease, or other noninfectious post-transplant complications involving the lungs. Methods: A case example is provided to illustrate the difficulties in management of busulfan-induced lung injury in children. A retrospective review of cases of busulfan-induced lung injury indexed in PubMed until March 2019 was performed. Inclusion criteria for articles was available in full text in English. Results: Impaired lung function caused by busulfan may become an increasing problem for young survivors. Conclusion: Newly developed dyspnea or subclinical damage detected on pulmonary function tests, indicating primarily restrictive disease, should always arouse suspicion of busulfan-induced lung injury in a child conditioned with busulfan, especially after excluding other leading culprits of pulmonary damage affecting oncology patients. Copyright 2019, Mary Ann Liebert, Inc., publishers.
Background: Impaired lung function has been detected in up to 65% of all childhood cancer survivors. It is often caused by exposure to radiation therapy and various chemotherapeutics. The first cytotoxic drug ever identified as a causative agent of lung injury was busulfan, reported in the early 1960s. Signs and symptoms of busulfan lung are nonspecific and it is therefore difficult to differentiate the condition from pulmonary impairment caused by other pulmotoxic agents, infections, pulmonary metastases, graft-versus-host disease, or other noninfectious post-transplant complications involving the lungs. Methods: A case example is provided to illustrate the difficulties in management of busulfan-induced lung injury in children. A retrospective review of cases of busulfan-induced lung injury indexed in PubMed until March 2019 was performed. Inclusion criteria for articles was available in full text in English. Results: Impaired lung function caused by busulfan may become an increasing problem for young survivors. Conclusion: Newly developed dyspnea or subclinical damage detected on pulmonary function tests, indicating primarily restrictive disease, should always arouse suspicion of busulfan-induced lung injury in a child conditioned with busulfan, especially after excluding other leading culprits of pulmonary damage affecting oncology patients. Copyright 2019, Mary Ann Liebert, Inc., publishers.
Authors: Christopher Bredeson; Jennifer LeRademacher; Kazunobu Kato; John F Dipersio; Edward Agura; Steven M Devine; Frederick R Appelbaum; Marcie R Tomblyn; Ginna G Laport; Xiaochun Zhu; Philip L McCarthy; Vincent T Ho; Kenneth R Cooke; Elizabeth Armstrong; Angela Smith; J Douglas Rizzo; Jeanne M Burkart; Marcelo C Pasquini Journal: Blood Date: 2013-09-30 Impact factor: 22.113
Authors: P Crilley; D Topolsky; M J Styler; E Bernstein; K Resnick; R Mullaney; S Bulova; I Brodsky; D I Marks Journal: Bone Marrow Transplant Date: 1995-03 Impact factor: 5.483
Authors: Matthew Ulrickson; Julie Aldridge; Haesook T Kim; Ephraim P Hochberg; Peter Hammerman; Christine Dube; Eyal Attar; Karen K Ballen; Bimalangshu R Dey; Steven L McAfee; Thomas R Spitzer; Yi-Bin Chen Journal: Biol Blood Marrow Transplant Date: 2009-09-01 Impact factor: 5.742
Authors: Mona G Elhadidy; Ahlam Elmasry; Hassan Reda Hassan Elsayed; Mohammad El-Nablaway; Shereen Hamed; Mahmoud M Elalfy; Mohammed R Rabei Journal: Heliyon Date: 2021-10-13